Complement Activation Induces Neutrophil Adhesion and Neutrophil-Platelet Aggregate Formation on Vascular Endothelial Cells

Riedl, 2014, Spectrum of complement-mediated thrombotic microangiopathies: pathogenetic insights identifying novel treatment approaches, Semin Thromb Hemost, 40, 444, 10.1055/s-0034-1376153 Merle, 2015, Complement system part I—molecular mechanisms of activation and regulation, Front Immunol, 6, 262, 10.3389/fimmu.2015.00262 Merle, 2015, Complement system part II: role in immunity, Front Immunol, 6, 257, 10.3389/fimmu.2015.00257 De Vriese, 2015, Kidney disease caused by dysregulation of the complement alternative pathway: an etiologic approach, J Am Soc Nephrol, 26, 2917, 10.1681/ASN.2015020184 Morgan, 2016, The membrane attack complex as an inflammatory trigger, Immunobiology, 221, 747, 10.1016/j.imbio.2015.04.006 Noris, 2013, Overview of complement activation and regulation, Semin Nephrol, 33, 479, 10.1016/j.semnephrol.2013.08.001 Fremeaux-Bacchi, 2013, Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide french series comparing children and adults, Clin J Am Soc Nephrol, 8, 554, 10.2215/CJN.04760512 Bresin, 2013, Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype, J Am Soc Nephrol, 24, 475, 10.1681/ASN.2012090884 Camous, 2011, Complement alternative pathway acts as a positive feedback amplification of neutrophil activation, Blood, 117, 1340, 10.1182/blood-2010-05-283564 Huber-Lang, 2002, Generation of C5a by phagocytic cells, Am J Pathol, 161, 1849, 10.1016/S0002-9440(10)64461-6 Crew, 2005, De novo thrombotic microangiopathy following treatment with sirolimus: report of two cases, Nephrol Dial Transplant, 20, 203, 10.1093/ndt/gfh334 Meehan, 2011, Thrombotic microangiopathy and peritubular capillary C4d expression in renal allograft biopsies, Clin J Am Soc Nephrol, 6, 395, 10.2215/CJN.05870710 Noone, 2016, Von Willebrand Factor regulates complement on endothelial cells, Kidney Int, 90, 123, 10.1016/j.kint.2016.03.023 Cote, 2014, Secretoglobin 1A1 and 1A1A differentially regulate neutrophil reactive oxygen species production, phagocytosis and extracellular trap formation, PLoS One, 9, e96217, 10.1371/journal.pone.0096217 Patel, 2012, The cell motility modulator Slit2 is a potent inhibitor of platelet function, Circulation, 126, 1385, 10.1161/CIRCULATIONAHA.112.105452 Triantafilou, 2013, The complement membrane attack complex triggers intracellular Ca2+ fluxes leading to NLRP3 inflammasome activation, J Cell Sci, 126, 2903, 10.1242/jcs.124388 Turner, 1996, Phorbol ester-enhanced noradrenaline secretion correlates with the presence and activity of protein kinase C-alpha in human SH-SY5Y neuroblastoma cells, J Neurochem, 66, 2381, 10.1046/j.1471-4159.1996.66062381.x Liszewski, 2000, Dissecting sites important for complement regulatory activity in membrane cofactor protein (MCP; CD46), J Biol Chem, 275, 37692, 10.1074/jbc.M004650200 Jurianz, 1999, Neutralization of complement regulatory proteins augments lysis of breast carcinoma cells targeted with rhumAb anti-HER2, Immunopharmacology, 42, 209, 10.1016/S0162-3109(99)00006-5 Soltis, 1979, The effect of heat inactivation of serum on aggregation of immunoglobulins, Immunology, 36, 37 Heinen, 2013, Monitoring and modeling treatment of atypical hemolytic uremic syndrome, Mol Immunol, 54, 84, 10.1016/j.molimm.2012.10.044 Chaturvedi, 2013, Slit2 prevents neutrophil recruitment and renal ischemia-reperfusion injury, J Am Soc Nephrol, 24, 1274, 10.1681/ASN.2012090890 Cochrane, 1970, Depletion of plasma complement in vivo by a protein of cobra venom: its effect on various immunologic reactions, J Immunol, 105, 55, 10.4049/jimmunol.105.1.55 Heinen, 2007, Hemolytic uremic syndrome: a factor H mutation (E1172Stop) causes defective complement control at the surface of endothelial cells, J Am Soc Nephrol, 18, 506, 10.1681/ASN.2006091069 Jozsi, 2008, Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency, Blood, 111, 1512, 10.1182/blood-2007-09-109876 George, 2014, Syndromes of thrombotic microangiopathy, N Engl J Med, 371, 654, 10.1056/NEJMra1312353 Noris, 2009, Atypical hemolytic-uremic syndrome, N Engl J Med, 361, 1676, 10.1056/NEJMra0902814 Legendre, 2013, Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome, N Engl J Med, 368, 2169, 10.1056/NEJMoa1208981 Loirat, 2016, An international consensus approach to the management of atypical hemolytic uremic syndrome in children, Pediatr Nephrol, 31, 15, 10.1007/s00467-015-3076-8 Kilgore, 1998, Neutrophil adhesion to human endothelial cells is induced by the membrane attack complex: the roles of P-selectin and platelet activating factor, Inflammation, 22, 583, 10.1023/A:1022362413939 Noris, 2014, Dynamics of complement activation in aHUS and how to monitor eculizumab therapy, Blood, 124, 1715, 10.1182/blood-2014-02-558296 Hidalgo, 2009, Heterotypic interactions enabled by polarized neutrophil microdomains mediate thromboinflammatory injury, Nat Med, 15, 384, 10.1038/nm.1939 Zarbock, 2007, Platelet-neutrophil-interactions: linking hemostasis and inflammation, Blood Rev, 21, 99, 10.1016/j.blre.2006.06.001 Licht, 2009, Platelet-associated complement factor H in healthy persons and patients with atypical HUS, Blood, 114, 4538, 10.1182/blood-2009-03-205096 Morigi, 2011, Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis, J Immunol, 187, 172, 10.4049/jimmunol.1100491 Krisinger, 2012, Thrombin generates previously unidentified C5 products that support the terminal complement activation pathway, Blood, 120, 1717, 10.1182/blood-2012-02-412080